BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral activity in vivo

Cancer Research

Volumn 64, Issue 13, 2004, Pages 4621-4628

  Kuo, Ching Chuan ^a   Hsieh, Hsing Pang ^a   Pan, Wen Yu ^a   Chen, Ching Ping ^a   Liou, Jing Ping ^a   Lee, Shiow Ju ^a   Chang, Yi Ling ^a   Chen, Li Tzong ^a   Chen, Chiung Tong ^a   Chang, Jang Yang ^a,b  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

6 METHOXY 3 (3',4',5' TRIMETHOXYBENZOYL) 1H INDOLE; CASPASE 3; COLCHICINE; CYCLIN B1; INDOLE DERIVATIVE; PACLITAXEL; PROTEIN BCL 2; PROTEIN KINASE; PROTEIN TYROSINE PHOSPHATASE; TUBULIN; UNCLASSIFIED DRUG; VINCRISTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BINDING SITE; CELL CYCLE; CELL CYCLE G2 PHASE; CONTROLLED STUDY; CYTOTOXICITY; DRUG PROTEIN BINDING; DRUG STRUCTURE; ENZYME ACTIVATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IC 50; MALE; MEMBRANE POTENTIAL; MICROTUBULE ASSEMBLY; MITOCHONDRIAL MEMBRANE; MITOSIS; MOUSE; NICK END LABELING; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TUMOR CELL LINE; TUMOR XENOGRAFT; UTERINE CERVIX CARCINOMA;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BINDING SITES; CELL DIVISION; CELL LINE, TUMOR; COLCHICINE; DRUG SCREENING ASSAYS, ANTITUMOR; G2 PHASE; HUMANS; INDOLES; KB CELLS; MALE; MICE; MICE, NUDE; MICROTUBULES; MITOCHONDRIA; MITOSIS; NEOPLASMS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-BCL-2; TUBULIN; TUBULIN MODULATORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 3042740981     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-3474     Document Type: Article

References (46)

1. Amos LA. Focusing-in on microtubules. Curr Opin Struct Biol 2000;10:236-41.
2. Margolis RL, Wilson L. Microtubule treadmilling: what goes around comes around. Bioessays 1998;20:830-6.
3. Wang LG, Liu XM, Kreis W, Budman DR. The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a review. Cancer Chemother Pharmacol 1999;44:355-61.
4. Jordan A, Hadfield JA, Lawrence NJ, McGown AT. Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle. Med Res Rev 1998;18:259-96.
5. Shi Q, Chen K, Morris-Natschke SL, Lee KH. Recent progress in the development of tubulin inhibitors as antimitotic antitumor agents. Curr Pharm Des 1998;4:219-48.
6. Dumontet C, Sikic BI. Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. J Clin Oncol 1999;17:1061-70.
7. Deng L, Tatebe S, Lin-Lee YC, Ishikawa T, Kuo MT. MDR and MRP gene families as cellular determinant factors for resistance to clinical anticancer agents. Cancer Treat Res 2002;112:49-66.
8. Pettit GR, Singh SB, Boyd MR, et al. Antineoplastic agents. 291. Isolation and synthesis of combretastatins A-4, A-5, and A-6(1a). J Med Chem 1995;38:1666-72.
9. Gwaltney SL, Imade HM, Barr KJ, et al. Novel sulfonate analogues of combretastatin A-4: potent antimitotic agents. Bioorg Med Chem Lett 2001;11:871-4.
10. Dowlati A, Robertson K, Cooney M, et al. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 2002;62:3408-16.
11. Griggs J, Metcalfe JC, Hesketh R. Targeting tumour vasculature: the development of combretastatin A4. Lancet Oncol 2001;2:82-7.
12. Liou JP, Chang CW, Song JS, et al. Synthesis and structure-activity relationship of 2-aminobenzophenone derivatives as antimitotic agents. J Med Chem 2002;45:2556-62.
13. Nam NH. Combretastatin A-4 analogues as antimitotic antitumor agents. Curr Med Chem 2003;10:1697-722.
14. Gaj CL, Anyanwutaku I, Chang YH, Cheng YC. Decreased drug accumulation without increased drug efflux in a novel MRP-overexpressing multidrug-resistant cell line. Biochem Pharmacol 1998;55:1199-211.
15. Ferguson PJ, Fisher MH, Stephenson J, Li DH, Zhou BS, Cheng YC. Combined modalities of resistance in etoposide-resistant human KB cell lines. Cancer Res 1988;48:5956-64.
16. Finlay GJ, Baguley BC, Wilson WR. A semiautomated microculture method for investigating growth inhibitory effects of cytotoxic compounds on exponentially growing carcinoma cells. Anal Biochem 1984;139:272-7.
17. Tahir SK, Kovar P, Rosenberg SH, Ng SC. Rapid colchicine competition-binding scintillation proximity assay using biotin-labeled tubulin. Biotechniques 2000;29: 156-60.
18. Tahir SK, Han EK, Credo B, et al. A-204197, a new tubulin-binding agent with antimitotic activity in tumor cell lines resistant to known microtubule inhibitors. Cancer Res 2001;61:5480-5.
19. Tahir SK, Nukkala MA, Zielinski Mozny NA, et al. Biological activity of A-289099: an orally active tubulin-binding indolyloxazoline derivative. Mol Cancer Ther 2003; 2:227-33.
20. Cheng Y, Prusoff WH. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 1973;22:3099-108.
21. Bollag DM, McQueney PA, Zhu J, et al. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res 1995;55: 2325-33.
22. Blagosklonny MV, Schulte TW, Nguyen P, Mimnaugh EG, Trepel J, Neckers L. Taxol induction of p21WAF1 and p53 requires c-raf-1. Cancer Res 1995;55:4623-6.
23. Jett JH. Mathematical analysis of DNA: histograms from asynchronous and synchronous cell populations, In: D. Lutz, editor. Pulse Cytophotometry. Brussels: European Press; 1978. p. 93-102.
24. Zamzami N, Metivier D, Kroemer G. Quantitation of mitochondrial transmembrane potential in cells and in isolated mitochondria. Methods Enzymol 2000;322:208-13.
25. Chen CT, Gan Y, Au JL, Wientjes MG. Androgen-dependent and -independent human prostate xenograft tumors as models for drug activity evaluation. Cancer Res 1998;58:2777-83.
26. Krajewski S, Tanaka S, Takayama S, Schibler MJ, Fenton W, Reed JC. Investigation of the subcellular distribution of the bcl-2 oncoprotein: residence in the nuclear envelope, endoplasmic reticulum, and outer mitochondrial membranes. Cancer Res 1993;53:4701-14.
27. Haldar S, Basu A, Croce CM. Bcl2 is the guardian of microtubule integrity. Cancer Res 1997;57:229-33.
28. Li P, Nijhawan D, Budihardjo I, et al. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 1997;91:479-89.
29. Cohen GM. Caspases: the executioners of apoptosis. Biochem J 1997;326:1-16.
30. Ben Sasson SA, Sherman Y, Gavrieli Y. Identification of dying cells in situ staining. Methods Cell Biol 1995;46:29-39.
31. King KL, Cidlowski JA. Cell cycle and apoptosis: common pathways to life and death. J Cell Biochem 1995;58:175-80.
32. Kumagai A, Dunphy WG. The cdc25 protein controls tyrosine dephosphorylation of the cdc2 protein in a cell-free system. Cell 1991;64:903-14.
33. Strausfeld U, Labbe JC, Fesquet D, et al. Dephosphorylation and activation of a p34cdc2/cyclin B complex in vitro by human CDC25 protein. Nature 1991;351: 242-5.
34. Hoffmann I, Clarke PR, Marcote MJ, Karsenti E, Draetta G. Phosphorylation and activation of human cdc25-C by cdc2-cyclin B and its involvement in the self-amplification of MPF at mitosis. EMBO J 1993;12:53-63.
35. Sorger PK, Dobles M, Toumebize R, Hyman AA. Coupling cell division and cell death to microtubule dynamics. Curr Opin Cell Biol 1997;9:807-14.
36. Davis FM, Tsao TY, Fowler SK, Rao PN. Monoclonal antibodies to mitotic cells. Proc Natl Acad Sci USA 1983;80:2926-30.
37. Scatena CD, Stewart ZA, Mays D, et al. Mitotic phosphorylation of Bcl-2 during normal cell cycle progression and Taxol-induced growth arrest. J Biol Chem 1998; 273:30777-84.
38. Blagosklonny MV, Giannakakou P, el Deiry WS, et al. Raf-1/bcl-2 phosphorylation: a step from microtubule damage to cell death. Cancer Res 1997;57:130-5.
39. Srivastava RK, Srivastava AR, Korsmeyer SJ, Nesterova M, Cho-Chung YS, Longo DL. Involvement of microtubules in the regulation of Bcl2 phosphorylation and apoptosis through cyclic AMP-dependent protein kinase. Mol Cell Biol 1998;18: 3509-17.
40. Yamamoto K, Ichijo H, Korsmeyer SJ. BCL-2 is phosphorylated and inactivated by an ASK1/Jun N-terminal protein kinase pathway normally activated at G(2)/M. Mol Cell Biol 1999;19:8469-78.
41. Kluck RM, Bossy-Wetzel E, Green DR, Newmeyer DD. The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science 1997;275:1132-6.
42. Marchetti P, Castedo M, Susin SA, et al. Mitochondrial permeability transition is a central coordinating event of apoptosis. J Exp Med 1996;184:1155-60.
43. Susin SA, Lorenzo HK, Zamzami N, et al. Mitochondrial release of caspase-2 and -9 during the apoptotic process. J Exp Med 1999;189:381-94.
44. Susin SA, Zamzami N, Castedo M, et al. The central executioner of apoptosis: multiple connections between protease activation and mitochondria in Fas/APO-1/ CD95- and ceramide-induced apoptosis. J Exp Med 1997;186:25-37.
45. Beckers T, Reissmann T, Schmidt M, et al. 2-Aroylindoles, a novel class of potent, orally active small molecule tubulin inhibitors. Cancer Res 2002;62:3113-9.
46. Mahboobi S, Pongratz H, Hufsky H, et al. Synthetic 2-aroylindole derivatives as a new class of potent tubulin-inhibitory, antimitotic agents. J Med Chem 2001;44: 4535-53.